test

Mark Gottlieb

@Altium Capital Management Lp

Latest period2024 - Q3ReportedManaged Assets$339.708MTotal holdings77
Assets growth rate-99.86%Assets growth rate (2-Q avg)-51.42%Continuous growth in asset value0 quarters

Portfolio positions

This chart displays the top 10 holdings in Altium Capital Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 77 positions.

Assets under management

The assets under management (AUM) of Altium Capital Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 339.708M in assets, with a quarterly growth rate of -99.86% and a 2-quarter average growth rate of -51.42%. The portfolio is managed by Mark Gottlieb, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
VERAVera Therapeutics Inc
Recent Activity
Decreased -4.2%
8.9%
$30.233M
684,000 shares@ $44.2 avg price
ADMAAdma Biologics Inc
Recent Activity
Decreased -9.93%
8.01%
$27.186M
1.36M shares@ $19.99 avg price
ITCIIntra-cellular Therapies Inc
Recent Activity
Decreased -20.2%
3.32%
$11.268M
154,000 shares@ $73.17 avg price
INSMInsmed Inc
Recent Activity
Decreased -31.57%
2.8%
$9.49M
130,000 shares@ $73.0 avg price
CPRXCatalyst Pharmaceuticals Inc
Recent Activity
Decreased -23%
2.26%
$7.654M
385,000 shares@ $19.88 avg price
CTNMContineum Therapeutics Inc
Recent Activity
Decreased -14.02%
2.08%
$7.065M
369,126 shares@ $19.15 avg price
SVRASavara Inc
Recent Activity
Decreased -1.25%
1.97%
$6.678M
1.575M shares@ $4.24 avg price
SKYESkye Bioscience Inc
Recent Activity
Decreased -2.58%
1.52%
$5.142M
1.315M shares@ $3.92 avg price
ORICOric Pharmaceuticals Inc
Recent Activity
Decreased -12.34%
1.08%
$3.639M
355,000 shares@ $10.25 avg price
MLTXMoonlake Immunotherapeutics
Recent Activity
Decreased -65.21%
0.6%
$2.017M
40,000 shares@ $50.42 avg price